<?xml version="1.0" encoding="UTF-8"?>
<p id="Par61">Antioxidants that inhibit the detrimental consequences of ROS are generally considered as promising therapeutic approach to neuroprotection [
 <xref ref-type="bibr" rid="CR32">32</xref>]. An imbalance between the generation of ROS and the activity of antioxidant defence against ROS has been implicated in depression [
 <xref ref-type="bibr" rid="CR33">33</xref>]. Oxidative stress caused by excessive ROS production has received considerable attention in recent years and has been proposed as a contributing factor to the pathophysiology of depression [
 <xref ref-type="bibr" rid="CR34">34</xref>]. Furthermore, Behr et al. [
 <xref ref-type="bibr" rid="CR35">35</xref>] highlighted the antioxidant effects of antidepressant drugs and the mechanisms of antioxidants executing the neuroprotective capabilities in the treatment of major depressive disorder (MDD).
</p>
